Imunon Appoints Dr. Douglas V. Faller As Chief Medical Officer

Feb 10, 2025•6 months ago

Position

Chief Medical Officer

Company

IMUNON

Douglas V. Faller

LawrencevilleBiotechnology

Description

IMUNON, Inc has announced the appointment of Dr. Douglas V Faller, MD, PhD, as chief medical officer. Dr Faller will lead the company’s clinical strategy, specifically focusing on advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer.

Company Information

Company

IMUNON

Location

Lawrenceville, New Jersey, United States

About

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months